Isis upbeat on prospects for US Kynamro approval and promising pipeline
This article was originally published in Scrip
Following an upbeat second quarter earnings report on 6 August and guidance for the rest of the year, antisense drug developer Isis Pharmaceuticals announced an offering of $175 million of convertible senior notes to repurchase debt previously issued by the company, to repurchase or redeem existing convertible notes and for general expenses.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.